Résumé
Purpose: Capecitabine is a relatively new oral fluoropyrimidine currently licensed for the treatment of colorectal and breast cancer. Results: It has the advantage of oral administration with good tolerability and comparable activity to intravenous 5-fluorouracil. Central neurotoxicity has been described in 5-fluorouracil-treated patients but there is little data regarding capecitabine. We report here a case of reversible capecitabine-induced encephalopathy progressing to coma. Discussion: Literature on fluoropyrimidine-related neurotoxicity will also be reviewed and possible mechanisms of the drug or its metabolites crossing the blood-brain barrier will be discussed.
langue originale | Anglais |
---|---|
Pages (de - à) | 276-278 |
Nombre de pages | 3 |
journal | Cancer Chemotherapy and Pharmacology |
Volume | 58 |
Numéro de publication | 2 |
Les DOIs | |
état | Publié - 1 août 2006 |
Modification externe | Oui |